226
Donor and Recipient Env from Heterosexual Transmission Pairs Require High Receptor Levels for Entry
Melissa Alexander*1, E Platt2, J Mulenga3, S Allen1, D Kabat2, C Derdeyn1, and E Hunter1
1Emory Univ, Atlanta, GA, US; 2Oregon Hlth Sci Univ, Portland, US; and 3Univ Teaching Hosp, Lusaka, Zambia
Background: Previous studies demonstrated that a
severe genetic bottleneck selects for viruses with compact, glycan-restricted
envelope (Env) glycoproteins
during heterosexual transmission of subtype C HIV-1. We hypothesized that the
compact hyper-variable domains of the newly transmitted Env
could enable the virus to use low levels of CD4 and CCR5, which could be
important for transmission across a mucosal surface.
Methods: NL4-3 based GFP-reporter proviral plasmids were constructed to express multiple donor
and recipient Env from 5 heterosexual transmission
pairs and the viruses expressed from these constructs were evaluated for their
ability to enter into a panel of HeLa cell lines
engineered to express different levels of CD4 and CCR5.
Results: Initial results from 2 of the 5
transmission pairs show that donor and recipient Env
entered into cells expressing high levels of CD4 and CCR5 with equal
efficiency, but their infectivity declined as CCR5 levels decreased. Neither
donor nor recipient Env could mediate entry when CD4
levels were limiting or CCR5 was absent. In contrast, a virus that expressed
the CXCR4-tropic NL43 Env successfully entered all
cells expressing both low and high levels of CD4, independent of CCR5 level.
Overall, there was no significant difference in the efficiency of entry between
the donor and recipient Env in the cell lines where
infection occurred.
Conclusions: There appears to be no difference in the
efficiency of receptor utilization between the donor and recipient Env in these HeLa-derived cell
lines. The requirement for high levels of CD4 and CCR5 by both newly
transmitted Env and those from chronic infection
suggests that the observed genetic bottleneck does not involve the ability to
utilize low levels of CD4 or CCR5 or both.
|